<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00516724</url>
  </required_header>
  <id_info>
    <org_study_id>KU36-96</org_study_id>
    <secondary_id>D0810C00004</secondary_id>
    <nct_id>NCT00516724</nct_id>
  </id_info>
  <brief_title>Study to Assess the Safety and Tolerability of a PARP Inhibitor in Combination With Carboplatin and/or Paclitaxel</brief_title>
  <official_title>A Phase I, Open-Label Study to Assess the Safety and Tolerability of KU-0059436 in Combination With Carboplatin, KU-0059436 in Combination With a Paclitaxel/Carboplatin T/C Doublet and KU-0059436 in Combination With Paclitaxel in the Treatment of Patients With Advanced Solid Tumours</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to identify a safe and tolerable dose of the drug KU-0059436
      that can be given in combination with carboplatin and/or Paclitaxel chemotherapy
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">June 29, 2007</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Actual">January 4, 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To establish the maximum tolerated dose (MTD) of KU 0059436 in combination with Paclitaxel/Carboplatin</measure>
    <time_frame>assessed at each visit</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To identify the dose limiting toxicity of the combination therapy</measure>
    <time_frame>assessed at each visit</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">189</enrollment>
  <condition>Triple Negative Metastatic Breast Cancer</condition>
  <condition>Advanced Ovarian Cancer</condition>
  <condition>Carboplatin</condition>
  <condition>Paclitaxel</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Carboplatin + KU-0059436</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Paclitaxel + KU-0059436</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Paclitaxel, Carboplatin + KU-0059436</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>KU-0059436 (AZD2281)(PARP inhibitor)</intervention_name>
    <description>oral</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Olaparib</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>intravenous injection</description>
    <arm_group_label>1</arm_group_label>
    <other_name>CBDCA</other_name>
    <other_name>ParaplatinÂ®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>KU-0059436 (AZD2281)(PARP inhibitor)</intervention_name>
    <description>Oral</description>
    <arm_group_label>2.</arm_group_label>
    <other_name>Olaparib</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>Intravenous injection</description>
    <arm_group_label>2.</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>KU-0059436 (AZD2281)(PARP inhibitor)</intervention_name>
    <description>Oral</description>
    <arm_group_label>3.</arm_group_label>
    <other_name>Olaparib</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel + Carboplatin</intervention_name>
    <description>Intravenous injection</description>
    <arm_group_label>3.</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female patients with a histologically or cytologically diagnosed malignant
             solid tumour

          -  Adequate bone marrow, hepatic and renal function

          -  Performance status of no more than 2 ( ECOG scale).

        Exclusion Criteria:

          -  Any chemotherapy, radiotherapy ( except palliative), endocrine or immunotherapy within
             4 weeks prior to entry

          -  Major surgery with 4 weeks of entering the study and must have recovered from effects
             of the major surgery

          -  More than two previous courses of platinum-containing chemotherapy

          -  Heavily pre-treated patients(&gt; 2 courses of previous chemotherapy and/or extensive
             irradiation leading to bone marrow deficiency) will be excluded from the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>130 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jane Robertson, BSc, MBCHB, MD</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dr Johann de Bono, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cancer Research UK, The Institute of Cancer Research, London, UK</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Prof Jan HM Schellens</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Netherlands Cancer Institute, Amsterdam, The Netherlands</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sutton</city>
        <state>Surrey</state>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Netherlands</country>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&amp;studyid=2679&amp;filename=CSR_Synopsis_D0810C00004(KU36-96).pdf</url>
    <description>KU36-96_CSR_Synopsis</description>
  </link>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>August 13, 2007</study_first_submitted>
  <study_first_submitted_qc>August 13, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 15, 2007</study_first_posted>
  <last_update_submitted>June 8, 2020</last_update_submitted>
  <last_update_submitted_qc>June 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>malignant solid tumours</keyword>
  <keyword>Poly(ADP ribose) polymerases</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Olaparib</mesh_term>
    <mesh_term>Poly(ADP-ribose) Polymerase Inhibitors</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_time_frame>AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure</ipd_time_frame>
    <ipd_access_criteria>When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.</ipd_access_criteria>
    <ipd_url>https://astrazenecagroup-dt.pharmacm.com/DT/Home</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

